On October 22, 2024, Novo Nordisk submitted a nomination to the FDA, arguing that semaglutide products belong on the Demonstrable Difficulties for Compounding (DDC) list due to the complexities associated with their formulations, delivery mechanisms, dosage forms, achievement of bioavailability, compounding processes, and physicochemical and analytical testing. The FDA has yet to make a final decision on whether to ban compounded versions of semaglutide
Options if Highmark won't cover Wegovy A denial isn't the end of the road
6 Eligibility is more restrictive than the licensed indication and varies by area
Dermatologist tested
I wanna skydive, bungee jump, ride a bull, parasail, ride roller coasters, I want to LIVE a normal life and have a normal relationship with food
Now we help your body follow.